Desloratadine at a dose of 5 once daily provides significant 24-hour symptom relief for patients with seasonal allergic rhinitis (SAR).
A study of 1,026 patients suggests there are no statistically significant differences provided by higher dosages of the drug, United States researchers say.
They randomised patients to 2.5 mg, 5 mg, 7.5 mg, 10 mg or 20 mg of desloratadine in a placebo-controlled, double-blind study of 24-hour efficacy. Efficacy was assessed using Day 2 data based on the mean change from baseline in the average AM instantaneous total symptom score over the treatment period.
Investigators from Schering-Plough Research Institute in Kenilworth, New Jersey, United States, also included AM/PM previous total nasal and non-nasal symptom scores and individual symptom scores as efficacy variables.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!